Prenatal MS drugs and child development: a large-scale safety check
A large historical cohort study has provided new data on the long-term safety of prenatal exposure to disease-modifying therapies (DMTs) for multiple sclerosis. Analyzing health records of over 1,300 children born to mothers with MS, researchers found that prenatal exposure to most DMTs, including interferons, glatiramer, and monoclonal antibodies, was not associated with a significant increased risk of neurodevelopmental disorders in offspring after an average follow-up of 7.5 years. However, a signal for a higher risk of major congenital anomalies was observed in the small subgroup of children exposed to sphingosine-1-phosphate receptor (S1PR) modulators, though the finding requires confirmation in larger, prospective studies.
Why it might matter to you:
This study directly addresses a critical evidence gap regarding the neurodevelopmental outcomes of children exposed to immunomodulatory drugs in utero. For researchers investigating the causes of neurodevelopmental disorders, it underscores the importance of pharmacoepidemiology in disentangling potential environmental and iatrogenic risk factors from genetic ones. The findings provide a more nuanced safety profile that can inform both clinical counseling for women with MS and future research into the mechanisms by which specific drug classes might affect fetal development.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
